In the years since 1975, a child diagnosed with cancer in the United States has gone from roughly a six-in-ten chance of surviving five years to nearly nine-in-ten, a shift that counts among modern medicine's most hopeful stories. Yet a new comprehensive review of registry records for more than 100,000 young patients shows that this hope has not been distributed evenly: Black children fare worse across most cancer types, and certain leukemias and sarcomas still resist cure. Researchers and clinicians see the reasons as tangled together, woven from access, insurance, geography and the biology o
Childhood Cancer Survival Nears 90%, but Gaps by Race and Cancer Type Persist
Children and adolescents with aggressive leukemias, sarcomas and high-risk neuroblastoma still face poorer survival, and Black children face worse survival across most cancer types.
Nearly nine in ten survive, but the gains did not reach everyone equally.
Mark
Nine in ten surviving five years sounds like a finished victory. Why isn't it?
Mimi
Because the average hides a lot. Acute lymphoblastic leukemia went from 43% to 95%, but AML is around 72% and sarcomas around 74%. Those children haven't had the same gains.
Mark
And the gap by race?
Mimi
For 2000 to 2017, non-Hispanic Black patients had 80.8% five-year survival, against 88% for non-Hispanic White patients. Black children had worse survival across most cancer types.
Luke
Careful, though. The study documents the gap; it doesn't explain it. Schwartz says the causes are probably a mix of access, insurance, geography, tumor biology and side effects, and she says we still need to learn which matters most.
Mark
So nobody knows the cause yet?
Luke
Not from this reporting. "Probably a mix" is a hypothesis, not a finding.
Mimi
What I find striking is the Hodgkin lymphoma figure. Survival was 87% at five years but 63% at 30 years for people treated in the 1970s and early 1980s.
Mark
So cured doesn't always mean safe long-term.
Mimi
Right, which is why she stresses lifelong follow-up, including screening for second cancers and heart problems.
Luke
One caveat: she credits targeted drugs and immunotherapy with improving survival, but the wording is "may have" and "likely." Those are plausible contributors, not proven causes. Also, the survival data runs through 2017, so it doesn't reflect the newest treatments.
Il Polso
- Five-year survival for young cancer patients has climbed to nearly nine in ten, yet the gains have not reached everyone equally.
- Black children face survival rates about seven points below White children across combined cancer types, a gap that refuses to close.
- Acute myeloid leukemia and sarcomas hover near 72 to 74 percent survival, leaving clinicians pressing for newer and better treatments.
- Survivors treated decades ago face rising late deaths, with a Hodgkin lymphoma cohort falling from 87 percent to 63 percent survival by thirty years.
- Researchers are working to untangle access, insurance, geography and biology so that every child can benefit from advances in therapy and lifelong care.
In the years since 1975, a child diagnosed with cancer in the United States has gone from roughly a six-in-ten chance of surviving five years to nearly nine-in-ten, a shift that counts among modern medicine's most hopeful stories. Yet a new comprehensive review of registry records for more than 100,000 young patients shows that this hope has not been distributed evenly: Black children fare worse across most cancer types, and certain leukemias and sarcomas still resist cure. Researchers and clinicians see the reasons as tangled together, woven from access, insurance, geography and the biology of disease itself. The lesson drawn is that survival is only part of the human measure, since the years after a cure carry their own long reckoning.
By 2017, nearly nine in ten young Americans diagnosed with cancer were still alive five years later, up from about six in ten in 1975. The finding comes from the first broad update of U.S. childhood cancer survival in more than a decade, led by pediatric oncologist Dr. Lindsay Schwartz of Chicago's Lurie Children's Hospital and her colleagues, who examined registry records for more than 100,000 children and teenagers diagnosed between 1975 and 2022.
Schwartz calls the progress one of medicine's greatest success stories, crediting targeted drugs and immunotherapies, sharper diagnostics and collaborative trials. But the gains were uneven. For cancers combined between 2000 and 2017, survival was 88 percent for non-Hispanic White patients and 80.8 percent for non-Hispanic Black patients, and Black children fared worse across most cancer types.
Disease type shapes the outlook as well. Acute lymphoblastic leukemia rose from 43 percent to 95 percent survival, while acute myeloid leukemia and sarcomas remain near 72 and 74 percent. Schwartz says these children need new treatments and that research should prioritize them.
The reasons for the gaps are not yet settled, probably a mix of access, insurance, residence, tumor biology and treatment side effects. Survival at five years also does not tell the full story. Hodgkin lymphoma survivors treated in the 1970s and early 1980s had 87 percent survival at five years but only 63 percent at thirty, often from treatment's long shadow. Schwartz stresses lifelong follow-up, and her twofold conclusion is clear: develop less toxic therapies, and ensure they reach every child.
By 2017, nearly nine in ten young people diagnosed with cancer in the United States were still alive five years later. In 1975, the figure was about six in ten. That is the headline of the first comprehensive update of U.S. childhood cancer survival statistics in more than a decade, published in the Journal of the National Cancer Institute.
The lead author is Dr. Lindsay Schwartz, a pediatric oncologist at Ann & Robert H. Lurie Children's Hospital of Chicago and an assistant professor of pediatrics at Northwestern University Feinberg School of Medicine. She and her colleagues examined registry records for more than 100,000 children and teenagers, ages 0 to 19, diagnosed between 1975 and 2022. The data came from the National Cancer Institute's SEER 8 and SEER 17 databases, and the team tracked five-year overall survival across different sociodemographic groups.
Schwartz calls childhood cancer one of modern medicine's greatest success stories. She points to molecularly targeted agents and immunotherapies, which have increasingly been built into treatment and may have helped young patients who were not cured by conventional chemotherapy, while also reducing late deaths from toxic treatments. Advances in precision diagnostics, risk stratification and inclusive cooperative group trials likely contributed too.
But the progress was not shared evenly. For all cancer types combined between 2000 and 2017, five-year survival was 88% for non-Hispanic White patients, 85.6% for patients of other races and ethnicities, 84.5% for Hispanic patients and 80.8% for non-Hispanic Black patients. Black children and teenagers had worse survival across most cancer types.
The picture also varies by disease. Acute lymphoblastic leukemia, the most common childhood cancer, went from 43% five-year survival in 1975 to 95% in 2017. Acute myeloid leukemia, by contrast, sits at around 72%, and sarcomas, cancers of bone and soft tissue, at around 74%. Schwartz said children with AML, sarcomas and high-risk neuroblastoma still need new and better treatments, and that research on them should be a priority.
Why the gaps persist is not settled. Schwartz said the reasons are probably a mix of factors: access to care, insurance, where families live, how the cancer behaves biologically, and treatment side effects. Learning which matters most, she said, is key to making sure every child benefits from medical advances.
Five-year survival is also not the whole measure. Some survivors, especially people treated for Hodgkin lymphoma decades ago, die at higher rates 20 to 30 years after being cured, often from long-term effects of treatment. Among those treated in the 1970s and early 1980s, survival was 87% at five years but only 63% at 30 years. Schwartz stressed that lifelong follow-up care matters, including screening for second cancers and heart problems.
The work was supported by the National Cancer Institute and the National Center for Advancing Translational Sciences at the NIH, the U.S. Department of Defense, Alex's Lemonade Stand Foundation, and the National Clinical Trials Network Operations Center Grant for the Children's Oncology Group. Schwartz's conclusion is twofold: keep developing effective, less toxic therapies, and make sure they reach every child and adolescent with cancer.
Citazioni salienti
The reasons for these gaps are probably a mix of factors: access to care, insurance, where families live, how the cancer behaves biologically and treatment side effects.— Dr. Lindsay Schwartz, lead author, Lurie Children's Hospital of Chicago
For AML, sarcomas and high-risk neuroblastoma, children still need new and better treatments, and research on them should be a priority.— Dr. Lindsay Schwartz
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗